Jupiter Neurosciences Grants Over 3 Million Options to Executives and Directors, Pays Bonuses in Equity Amidst Cash Constraints
JUNS sits 45% above its 52-week low of $0.172.
Summary
Jupiter Neurosciences is compensating executives and directors with over 3.2 million stock options, including bonuses paid in equity instead of cash, highlighting severe cash constraints and potential future dilution.
Key Events · Executive and Board Changes · JUNS
-
Executive Promotion and Salary Increase
Alison Silva was promoted to Chief Operating Officer and President, with her base salary increasing to $340,200 from $315,000. She also received a one-time grant of 600,000 stock options.
-
Significant Option Grants to Executives
The company approved discretionary bonuses for its CEO (Christer Rosén), COO & President (Alison Silva), CFO (Saleem Elmasri), CSO (Marshall Hayward), and CAO (Alexander Rosén) in the form of stock options, totaling over 2.1 million options. Mr. Elmasri received an additional 200,000 options.
-
Bonuses Paid in Equity Instead of Cash
A critical detail is that these discretionary executive bonuses were explicitly approved 'in lieu of cash,' indicating the company's severe liquidity challenges.
-
Director Option Grants
Independent non-employee directors were granted options to purchase up to 100,000 shares each, vesting over three years.
Analysis · JUNS · Life Sciences
This filing reveals Jupiter Neurosciences is heavily relying on equity compensation to conserve cash, a strong indicator of its ongoing financial distress. The company granted over 3.2 million stock options to its CEO, CFO, COO, other executives, and independent directors, with a significant portion of executive bonuses being paid in options instead of cash. This strategy, while preserving immediate cash, introduces substantial potential dilution for existing shareholders, especially given the company's recent history of 'going concern' warnings and dilutive financing activities.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUNS was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.17 to $3.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.